MACK Stock Overview
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Merrimack Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.26 |
| 52 Week High | US$13.66 |
| 52 Week Low | US$3.00 |
| Beta | 1.72 |
| 1 Month Change | 0.16% |
| 3 Month Change | -0.24% |
| 1 Year Change | 234.06% |
| 3 Year Change | 210.38% |
| 5 Year Change | 143.74% |
| Change since IPO | -79.70% |
Recent News & Updates
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23
Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19Recent updates
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05Shareholder Returns
| MACK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | -1.4% | -1.1% |
| 1Y | 234.1% | 6.2% | 14.1% |
Return vs Industry: MACK exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: MACK exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| MACK volatility | |
|---|---|
| MACK Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.1% |
| 10% least volatile stocks in US Market | 2.6% |
Stable Share Price: MACK is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: MACK's weekly volatility has decreased from 31% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Gary Crocker | https://www.merrimack.com |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc. Fundamentals Summary
| MACK fundamental statistics | |
|---|---|
| Market Cap | US$176.58m |
| Earnings (TTM) | -US$1.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-110.0x
P/E RatioIs MACK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MACK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.60m |
| Earnings | -US$1.60m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MACK perform over the long term?
See historical performance and comparison